Testing a new pill for CML after other treatments
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic myeloid leukemia (CML) that is in the chronic phase (not accelerated or blast crisis).
- You have tried at least one TKI (targeted cancer pill) and it either didn't work well, stopped working, or caused bad side effects.
- You are physically able to do most daily activities (ECOG score 0, 1, or 2).
- You have not had any other cancer treatment in the last 7 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This Phase 1 study tests ELVN-001 in people with chronic-phase chronic myeloid leukemia (CML) who have had limited benefit or side effects from other CML medicines. It may help shrink leukemia activity safely and find the best dosing for people who still need treatment options.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
Hear when a new Chronic Myeloid Leukemia, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.